Edesa Biotech, Inc.

Edesa Biotech, Inc. reported a net loss of $2.2 million for Q1 2026 (period ending December 31, 2025), representing a quarterly loss per share of $0. The company's operations generated a loss of $2.3 million, driven by research and development expenses of $1.1 million and general and administrative expenses of $1.2 million. Nonoperating income of $94,000, primarily from a $102,000 reimbursement grant, partially offset the operational losses. The company's cash position improved by $1.3 million during the quarter to $12.1 million, supported by $3.4 million in net financing activities from common share issuances. Total assets stood at $14.7 million with shareholders' equity of $14.0 million, while accumulated deficit reached $68.2 million. The company continues to operate without generating revenue, focusing resources on research and development activities.

Key Takeaways